IRCT20090117001556N125
Not yet recruiting
Phase 2
Studying the effects of Celecoxib as monotherapy in the treatment of postpartum depression with mild intensity to the average: response to treatment of Celecoxib by area Brain-Derived Neurotrophic Factor (BDNF) and inflammatory cytokines (TNFa, IFN? , IL-1?, IL-1? IL-6, IL-8)
Overview
- Phase
- Phase 2
- Status
- Not yet recruiting
- Enrollment
- 50
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 45 years (—)
- Sex
- Female
Inclusion Criteria
- •Age between 18 to 45
- •Having mild to moderate depression according to Hamilton Depression Rating Scale (HAM\-D)
Exclusion Criteria
- •Having severe depression according to Hamilton Depression Rating Scale (HAM\-D or HDRS)
- •Addiction to drugs
- •Addiction to alcohol
- •Presence of Thyroid disease
- •Receiving any antidepressant medications during past one month prior to the trial
- •Receiving Electroconvulsive therapy during past two months prior to the trial
- •Any other diagnosis according to axis\-1, DSM\-5
- •Having a risk of suicide based on doctor's clinical judgement or having a score of \>2 in suicide item of Hamilton Depression Rating Scale (HAM\-D or HDRS)
- •Concomitant use of medications that increase the risk of gastrointestinal bleeding
- •Presence of cardiovascular disease
Investigators
Similar Trials
Suspended
Not Applicable
A clinical study on the efficacy of celecoxib in patients with postoperative pain (A multicenter, randomized, open-label,parallel-group controlled study of celecoxib vs. loxoprofen)The subjects will be patients who are anticipated to develop postoperative pain that is determined manageable with oral NSAIDsJPRN-UMIN000011302ippon Medical School Department of Orthopaedic Surgery230
Completed
Phase 2
Efficacy of celecoxib in the treatment of bipolar disorderIRCT201307171556N53Tehran University of Medical Sciences50
Recruiting
Phase 3
The effect of Celecoxib in the treatment of SchizophreniaIRCT20210831052351N1niversity of social welfare and rehabilitation sciences52
Recruiting
Phase 3
Effects of add-on Celecoxib treatment in patients with schizophrenia spectrum disorders and inflammatory cytokine profile (TargetFlame)Schizophrenie oder schizophrene Spektrum-erkrankungF20SchizophreniaDRKS00029044Bezirkskliniken Schwaben109
Active, not recruiting
Phase 1
Effects of add-on Celecoxib treatment in patients with schizophrenia spectrum disorders and inflammatory cytokine profile (TargetFlame)EUCTR2021-002572-39-DEBezirkskliniken Schwaben109